Table 4 Contribution of each serum marker and CTCs to a clinical model

Triple neg.

3.05

(2.14; 4.36)

3.55

(2.43; 5.18)

3.33

(2.06; 5.39)

3.27

(2.03; 5.30)

3.14

(1.95; 5.06)

4.417

(2.628; 7.425)

3.061

(1.89; 4.95)

3.344

(2.062; 5.423)

PS > 0

2.30

(1.65; 3.21)

2.659

(1.89; 3.741)

2.097

(1.319; 3.33)

2.359

(1.509; 3.69)

2.133

(1.35; 3.36)

2.428

(1.56; 3.78)

1.968

(1.21; 3.19)

2.49

(1.58; 3.93)

Nb of metastatic sites > 2

1.886

(1.378; 2.581)

NS

CTC ≥ 5

2.263

(1.644; 3.115)

1.996

(1.277; 3.122)

CA15-3 ≥ ULNV

1.665

(1.167; 2.374)

1.746

(1.095; 2.783)

CYFRA 21-1 ≥ ULNV

2.901

(1.896; 4.439)

2.097

(1.27; 3.46)

CEA ≥ ULNV

1.64

(1.151; 2.337)

2.015

(1.272; 3.191)

LDH ≥ ULNV

2.525

(1.781; 3.579)

1.933

(1.203; 3.104)

ALP ≥ ULNV

1.501

(1.058; 2.131)

1.108

(0.684; 1.793)

C-INDEX

0.697

(0.65; 0.75)

0.71

(0.663; 0.767)

0.713

(0.661; 0.765)

0.723

(0.68; 0.77)

0.714

(0.664; 0.765)

0.717

(0.668; 0.766)

0.688

(0.637; 0.74)